VIP and rheumatoid arthritis: In addition, VIP decreases proinflammatory mediators in lymphocytes and FLS from RA patients [21, 38, 48–50] and modulates the differentiation of several Th cells from RA patients, including a decrease in the pathogenic profile and plasticity of some of them [21, 50, 51].